Rigel Pharmaceuticals receives Nasdaq deficiency notice for bid price below $1.00

RIGEL PHARMACEUTICALS INC

Nasdaq notified Rigel on Nov 22, 2022 that its common stock bid price closed below $1.00 for 30 consecutive business days.
Rigel has 180 calendar days, until May 22, 2023, to regain compliance by closing at $1.00 or more for at least 10 consecutive business days.
If not compliant by May 22, Rigel may be eligible for an additional 180-day period if it meets other listing standards and intends to cure via reverse stock split.
Failure to regain compliance could lead to delisting; Rigel may appeal a delisting determination.
No immediate effect on Nasdaq listing; stock continues to trade under RIGL.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.